Physician profile

Elliot Pohlmann

Psychiatry · San Diego, CA

NPI 1407233208

$397.38

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$183.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $266.95 2022-2023
Lilly USA, LLC $27.45 2023 Mounjaro
Biohaven Pharmaceutical Holding Company Ltd. $21.58 2022
Daiichi Sankyo INC. $18.86 2023 Injectafer
Exact Sciences Corporation $18.12 2023 Cologuard Collection Kit
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $16.05 2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $14.46 2023 Xifaxan
Otsuka America Pharmaceutical, INC. $13.91 2023 Rexulti

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Elliot Pohlmann

$397.38

in general payments reported 2019-2025

Years
2022-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/9544387/elliot-pohlmann

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.